Clear coverage of hospitals, insurance, pharma, and Washington.
Aggressive state-level enforcement could dismantle drugmakers' data mandates, lowering compliance barriers for 340B covered entities while exposing pharmaceutical companies to state legal and regulatory liabilities.
The shutdown poses a critical setback for the biopharma sector's high-profile push to repurpose oncology cell therapies for autoimmune diseases, likely prompting intensified regulatory scrutiny and clinical protocol reassessments across peer pipelines.
Clarifying the regulatory framework for customized therapies reduces development uncertainty for biopharma companies, paving the way for scalable investment in ultra-rare, individualized genetic medicines.
A rising profile for Kennedy's MAHA agenda could pressure federal regulators to overhaul food and drug oversight, while impending outbound investment rules risk disrupting cross-border biotech financing and drug development pipelines.